SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

ProMIS Neurosciences Inc.
Date: Sept. 8, 2025 · CIK: 0001374339 · Accession: 0000000000-25-009669

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290039

Date
September 8, 2025
Author
Division of
Form
UPLOAD
Company
ProMIS Neurosciences Inc.

Letter

Re: ProMIS Neurosciences Inc. Registration Statement on Form S-3 Filed September 4, 2025 File No. 333-290039 Dear Neil Warma:

September 8, 2025

Neil Warma Chief Executive Officer ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto, Ontario M4S 3E2

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Adam Johnson

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 8, 2025

Neil Warma
Chief Executive Officer
ProMIS Neurosciences Inc.
Suite 200, 1920 Yonge Street
Toronto, Ontario M4S 3E2

 Re: ProMIS Neurosciences Inc.
 Registration Statement on Form S-3
 Filed September 4, 2025
 File No. 333-290039
Dear Neil Warma:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Adam Johnson
</TEXT>
</DOCUMENT>